Analysts predict that Motus GI Holdings Inc (NASDAQ:MOTS) will announce earnings per share (EPS) of ($0.33) for the current quarter, according to Zacks. Zero analysts have made estimates for Motus GI’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.27). The company is scheduled to report its next quarterly earnings results on Wednesday, March 27th.
According to Zacks, analysts expect that Motus GI will report full-year earnings of ($1.33) per share for the current fiscal year, with EPS estimates ranging from ($1.41) to ($1.17). For the next fiscal year, analysts expect that the company will report earnings of ($1.00) per share, with EPS estimates ranging from ($1.27) to ($0.71). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Motus GI.
Motus GI (NASDAQ:MOTS) last announced its quarterly earnings data on Wednesday, November 14th. The company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.06).
A number of research analysts have recently commented on the stock. Zacks Investment Research raised shares of Motus GI from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Tuesday. Oppenheimer set a $10.00 price objective on shares of Motus GI and gave the company a “buy” rating in a research report on Monday, November 26th. Seven analysts have rated the stock with a buy rating, Motus GI presently has an average rating of “Buy” and an average price target of $9.50.
Shares of MOTS opened at $4.18 on Thursday. The stock has a market cap of $65.58 million and a PE ratio of -3.27. Motus GI has a 52 week low of $2.34 and a 52 week high of $10.66.
In other Motus GI news, CEO Timothy P. Moran purchased 15,000 shares of the company’s stock in a transaction that occurred on Monday, November 19th. The stock was purchased at an average price of $3.48 per share, with a total value of $52,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary E. Jacobs purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 24th. The stock was acquired at an average cost of $2.70 per share, with a total value of $27,000.00. The disclosure for this purchase can be found here. Insiders purchased 55,600 shares of company stock valued at $167,358 in the last three months.
A number of large investors have recently bought and sold shares of the stock. Private Advisor Group LLC acquired a new stake in shares of Motus GI during the third quarter worth approximately $105,000. Renaissance Technologies LLC acquired a new stake in shares of Motus GI during the third quarter worth approximately $139,000. Eaton Vance Management acquired a new stake in shares of Motus GI during the third quarter worth approximately $204,000. Finally, Lombard Odier Asset Management USA Corp increased its holdings in shares of Motus GI by 78.6% during the third quarter. Lombard Odier Asset Management USA Corp now owns 125,000 shares of the company’s stock worth $638,000 after buying an additional 55,000 shares in the last quarter. 22.17% of the stock is owned by hedge funds and other institutional investors.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Featured Story: Is the QQQ ETF safe?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.